News Releases

News Releases

2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010

2020

2020-12-21	Maruho Announces Executive Personnel Changes and New Executive Structure
2020-07-09	Maruho Announces New England Journal of Medicine Publication of Results from Phase 3 Clinical Study (Comparative Study) in Japan of Nemolizumab for the Treatment of Atopic Dermatitis
2020-04-01	Maruho Announces Transfer/Acquisition of Device for Pincer Nails “Makizume Meister®” Business and Establishment of the Medical Device Department

2019

2019-12-10	Maruho Enters an Exclusive License Agreement in Japan for SP-04, a Therapeutic Agent for Chemotherapy Induced Peripheral Neuropathy, and a Capital Alliance with Solasia
2019-12-02	Chugai Completes Transfer of Rights to Maruho for Oxarol® Ointment 25μg/g and Oxarol® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
2019-11-15	Maruho Establishes New Research Base -Installation of Satellite Lab at Shonan iPark-
2019-09-09	Maruho Preparing to Resume US Development For Anti-Herpes Virus Agent “Amenalief® Tab. 200mg”
2019-07-31	Maruho and KOSÉ Establish a Jointly Owned Company
2019-07-01	Maruho Establishes New US Subsidiary,“Maruho America Inc.”
2019-05-29	Maruho and Welby Launch Smartphone App “Atopi Note” to Support Patients with Atopic Dermatitis
2019-04-18	Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis
2019-03-29	Maruho Announces a Transfer of Shares and a Change of a Consolidated Subsidiary
2019-03-04	Maruho and Welby Launch Smartphone App “Nikibi Log” For Patients with Acne
2019-02-21	Maruho and Asahi Kasei Pharma Announce First Approval in Japan of an Additional Dosage and Administration for Anti-herpes Virus Agent "Famvir® Tab 250 mg" for the Treatment of Recurrent Herpes Simplex (Herpes labialis/Herpes genitalis)
2019-01-31	Maruho and KOSÉ Agree to Establish a Jointly Owned Company
2019-01-30	Chugai Transfers Rights to Maruho for Oxarol® Ointment 25μg/g and Oxarol® Lotion 25μg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris

2018

2018-10-01	National Cancer Center Japan and Maruho Enter License Agreement and Research Collaboration Agreement for a Novel Analgesic for Stomatitis in Cancer Treatment
2018-09-28	Maruho Succeeds Manufacturing and Marketing Approval and Marketing Rights for Acne Vulgaris Treatment Agent “Differin® Gel 0.1%”
2018-09-13	Maruho Launches Blood-flow Accelerative/Skin-moisturizing Agent “Hirudoid® Foam 0.3%”
2018-07-05	Nestlé Skin Health and Maruho Release Renewed Itch Measurement App ‘Itch Tracker’ for Apple Watch on July 5, Maruho Receives Exclusive Rights in Japan
2018-03-01	Maruho Succeeds Manufacturing and Marketing Approval and Marketing Rights for Reduction of Malodor Generated in Cancerous Cutaneous Ulcers Treatment “Rozex® Gel 0.75%”
2018-02-16	Maruho Receives Manufacturing and Marketing Approval for Blood-flow Accelerative/Skin-moisturizing Agent “Hirudoid® Foam 0.3%”
2018-01-22	Maruho Launches In Vitro Diagnostic “DermaQuick® VZV”

2017

2017-12-25	Maruho and RaQualia Enter License Agreement for Selective Sodium Channel Blocker
2017-11-30	Maruho and Asahi Kasei Pharma Announce Phase 3 Clinical Study Results of Famciclovir for the Treatment of Recurrent Herpes Simplex
2017-09-07	Maruho Launches Anti-Herpes Virus Agent “Amenalief® Tab. 200mg” in Japan
2017-09-01	Maruho Receives Manufacturing and Marketing Approval and Insurance Coverage for In Vitro Diagnostic “Derma Quick® VZV”
2017-08-01	Maruho Succeeds Manufacturing and Marketing Approval for Acne Vulgaris Treatment “Epiduo® Gel”
2017-07-11	Maruho Launches Topical Scalp Psoriasis Treatment “Comclo® Shampoo 0.05%” in Japan
2017-07-07	Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent “Protopic® Ointment” in Japan
2017-07-03	Maruho receives manufacturing and marketing approval for Anti-Herpes Virus Agent “Amenalief® Tab. 200mg” in Japan
2017-06-05	Maruho and the Japanese Dermatological Association announce the Joint Operation of the Maruho Prize
2017-03-30	Maruho receives manufacturing and marketing approval in Japan for Topical Scalp Psoriasis Treatment “Comclo® Shampoo 0.05%”
2017-03-14	Toray and Maruho Enter License Agreement for RORγt Inhibitor
2017-03-06	Cutanea (Maruho’s US Subsidiary) Unveils Aktipak™ (erythromycin and benzoyl peroxide) Gel, 3%/5%, Convenient Acne Treatment for "On-the-Go" Patients

2016

2016-12-09	The “Galderma Award” Transfers to Maruho
2016-11-04	Maruho Launches Acne Vulgaris Treatment “Epiduo® Gel” in Japan
2016-09-28	Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK Inhibitor peficitinib (ASP015K) for Treatment in the Skin Disease Area
2016-09-28	Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market
2016-09-21	Maruho enters a License Agreement with Dermira for Hyperhidrosis treatment agent DRM04
2016-09-16	Maruho launches infantile hemangioma treatment“Hemangiol® Syrup for Pediatric 0.375%” under a license from Pierre Fabre Laboratories
2016-07-20	Maruho and Galderma Strengthen Strategic Alliance in Japan
2016-07-04	Maruho receives manufacturing and marketing approval in Japan for infantile hemangioma treatment “Hemangiol® Syrup for Pediatric 0.375%” under a license from Pierre Fabre Laboratories
2016-02-22	Maruho Announces the Sixth Maruho Prize Winner, Award Ceremony and Lecture
2016-01-18	Maruho and Galderma to Join Forces in a Strategic Alliance in Japan

2015

2015-12-15	Maruho to Dissolve UK Subsidiary
2015-10-01	Maruho Merges its Consolidated US Subsidiaries
2015-09-28	Maruho receives manufacturing and marketing approval for quinolone anti-microbial topical treatment Zebiax® Lotion 2%
2015-09-25	Maruho submits a New Drug Application for Propranolol as the first drug for Infantile Hemangioma in Japan
2015-02-20	Maruho Announces the Fifth Maruho Prize Winner, Award Ceremony and Lecture

2014

2014-03-20	Maruho Announces the Fourth Maruho Prize Winner, Award Ceremony and Lecture

2013

2013-06-14	“Pain Relief in Laser Irradiation Treatment of the Skin” Approved as an Additional Indication for Penles®Tape 18mg, a Local Anesthetic Patch Preparation
2013-04-10	Announcement of the Third Maruho Prize Winner, Presentation Ceremony and Award Lecture.
2013-02-21	Approval of herpes simplex as additional indication for anti-herpes agent Famvir®Tab.
2013-01-17	Pierre Fabre and Maruho sign a licensing agreement in the treatment of severe infantile haemangioma

2012

2012-04-02	Maruho Establishes New Subsidiary in London, UK
2012-02-14	Maruho acquires Cutanea Life Sciences, Inc., U.S.A. Cutanea to become a wholly-owned subsidiary of Maruho.

2011

2011-10-03	Maruho Establishes New Subsidiary in the U.S.A.
2011-05-16	Maruho Funds Chemiderm to Sponsor Research Program at Harvard
2011-04-27	Dainippon Sumitomo Pharma and Maruho Enter into a License Agreement for a Novel Topical Analgesic Drug
2011-03-02	Hokunalin® Tape (tulobuterol patch), a long-acting transdermal bronchodilator, is now in new packages printed with the content on the tape surface and the barcode on the pouch

2010

2010-12-06	Marketing Collaboration on Protopic®Ointment for Treatment of Atopic Dermatitis in Japan
2010-11-12	Maruho founds the Maruho Prize. “To clinical dermatologists contributed to development the dermatology.”
2010-03-06	Maruho received Gold Triangle Awards 2010 by American Academy of Dermatology. This award recognizes Maruho Derma Report Issue #3 "Vitiligo Advancements" for raising public awareness of dermatologic issues.

About Maruho

To contribute to better health for people all over the world.

Copyright(c)2004-2020 Maruho Co.,Ltd. All rights reserved.

ACCESS	1-5-22 Nakatsu, Kita-ku, Osaka, Japan, 531-0071[Access]
TEL	+81-6-6371-8876